Comparative in silico study of congocidine congeners as potential inhibitors of African swine fever virus

Dickson Kinyanyi1*, Peris Amwayi1, Mark Wamalwa2, George Obiero3

1 Department of Biochemistry and Biotechnology, Technical University of Kenya, Nairobi, Kenya, 2 Department of Biochemistry and Biotechnology, Kenyatta University, Nairobi, Kenya, 3 Center for Biotechnology and Bioinformatics, University of Nairobi, Nairobi, Kenya

* dkinanyi@gmail.com

Abstract

African swine fever virus (ASFV) infection is fatal in domesticated pigs, with a mortality rate approaching 100%. This may result in economic losses and threats to food security. Currently, there are no approved vaccines or antiviral therapies for ASFV. Therefore, in this study, we evaluated congocidine congeners and a tris-benzimidazole as potential inhibitors of ASFV transcription using an in silico approach. We applied redocking of congocidine and docking of its congeners and a tris-benzimidazole to a receptor containing B-DNA with AT-motifs as a target to mimic conserved ASFV late gene promoters. Subsequently, the binding scores of DNA-ligand docked complexes were evaluated and their binding affinity was estimated. Molecular dynamics (MD) simulation was then used to assess ligand behavior within the minor groove. From our results, it is evident the less toxic congocidine congeners and tris-benzimidazole could dock to AT-rich regions significantly. Additionally, the predicted binding affinities had suitable values comparable to other experimentally determined minor groove binders, MD simulation of the docked DNA-ligand complexes and subsequent molecular trajectory visualization further showed that the ligands remained embedded in the minor groove during the time course of simulation, indicating that these ligands may have potential applications in abrogating ASFV transcription.

Introduction

DNA is a major target for various types of drugs [1]. Results from the analysis of several high-resolution structures suggest that the minor groove of DNA may function as a receptor for proteins and small molecules [2]. Moreover, drugs that bind to the minor groove may be exploited when pursuing a subset of viruses that replicate in the cytoplasm, such as the African swine fever (ASF) virus (ASFV). ASFV causes ASF, a fatal disease that affects domestic pigs. ASFV infection can affect the food supply, as pork is one of the most commonly consumed kinds of meat worldwide [3].

Currently, there are no vaccines or antiviral drugs approved for use against ASFV [4], and to date, reversible minor groove binders have not been applied or studied in mitigating ASFV
replication. A rational study of chemical compounds with potential antiviral activity against ASFV would be extremely useful in identifying prospective prophylactic or therapeutic agents to combat this catastrophic disease or design antivirals. Targeting of viral genomes by antiviral agents may inhibit viral replication and transcription [5–7]. Interestingly, ASFV has conserved AT-rich sequences suggestive of promoter motifs for late gene transcription [8–11], their replacement with equivalent CGCG sequences has been shown to be lethal in stagnating ASFV transcription [8,10]. Therefore, these uniquely conserved AT-rich motifs may serve as a suitable target for DNA minor groove binders in ASFV. Early computational and structural studies on alternating AT elements [12] and binding of ligands netropsin [13], Hoechst 33258 [14,15] and berenil [16] have shown that it is possible to target alternating AT elements of B-DNA minor groove. Significant efforts have been made towards understanding of structural and energetical aspects involved in ligand binding [17,18].

Accordingly, in this study, we analyzed the results of docking, binding affinity, and MD simulation of less toxic congocidine congeners and a tris-benzimidazole (Fig 1) to a DNA duplex having multiple combinations of AT motifs observed in core conserved ASFV late promoter regions in an attempt to simulate how these minor groove binders, which have never been used to treat ASF, could be applied as inhibitors for abrogating ASFV late gene transcription.

Materials and methods

Docking preparation

The two-dimensional (2D) structures of netropsin/congocidine and tris-benzimidazole were retrieved from PubChem [19] (https://pubchem.ncbi.nlm.nih.gov), whereas the congeners, congocidine 2 and congocidine 3 were sketched using the Edit molecule utility in the Internal Coordinate Mechanism (ICM) v3.83 algorithm [20]. The congeners were selected based on their documented minimal cytotoxicity [21], whereas the tris-benzimidazole was selected based on its possible bioisosteric ability to bind AT-rich motifs [22]. The starting structure, a netropsin-DNA complex (Protein Data Bank [PDB] ID 473D) [23] having a resolution of 1.58 Å, was retrieved from the PDB [24]. The 473D structure was selected based on the fact that d(CGTATATACG)2 has the K-mer signature motifs TATATA, ATAT, and TATA, which are similar to conserved AT-rich promoter motifs observed in the ASFV genome that are responsible for late gene transcription in ASFV [8–11]. The presence of nickel atoms observed in the decamer d(CGTATATACG)2 structure has been shown not to introduce any significant distortion in the oligonucleotide structure, whereas the characteristic alternating features of the central AT sequence in the B form of DNA are maintained [23]. The 473D PDB structure imported in ICM was prepared for docking, subsequent binding affinity calculations, and MD simulations by deleting all water molecules, optimizing hydrogen, deleting the unbound terminal guanines, terminal cytosines, terminal nickel atoms and adding the missing heavy atoms and hydrogen (S1 Data). Thereafter, the 473D derivative ligand-receptor complex was converted to an ICM object, and the netropsin ligand was moved from the receptor. The “setup receptor” tool was used to generate a receptor map of the binding site using a grid size of 0.5 Å.

Redocking and docking of ligands

Semi-flexible docking, which keeps the receptor rigid but the ligand flexible, was performed to predict binding modes of the ligands. The congocidine/netropsin ligand was redocked to the DNA duplexes (S2 Data) to get an estimate of the docking score (S) from the ICM algorithm (S1 Data). Docking of its congeners and the tris-benzimidazole then followed, and the top five
A: Congocidine 2\{2\{(4\{(4\{(4\{-\text{amino-imino-methylamino}\})\text{-acetylamino}\})\text{-1-methyl-1H-pyrrol-2-yl}\})\text{-formylamino}\})\text{-1-methyl-1H-pyrrol-2-yl}\})\text{-formylamino}\})\text{-1-methyl-1H-pyrrol-2-yl}\})\text{-formylamino}\})\text{-ethanimidamide}\}

B: Congocidine 3\{3\{(4\{(4\{-\text{amino-imino-methylamino}\})\text{-acetylamino}\})\text{-1-methyl-1H-pyrrol-2-yl}\})\text{-formylamino}\})\text{-1-methyl-1H-pyrrol-2-yl}\})\text{-formylamino}\})\text{-1-methyl-1H-pyrrol-2-yl}\})\text{-formylamino}\})\text{-butanenitride}\}

C: Tris-Benzimidazole 2\text{-\{4\{-methoxyphenyl\}\}}\text{-5\{-3\{-amino-1\{-pyrrolidinyl\}\}\}}\text{-2,5,2',5'-tri-benzimidazole\}
scoring values from the hit-list were kept for evaluation. ICM used a Monte Carlo global optimization procedure to predict binding poses for the ligand in the binding pocket [25]. The scoring function (S) in ICM is defined as the sum of energy changes when the ligand binds to the receptor, given as:

\[ \Delta S_{\text{bind}} = \Delta E_{\text{IntFF}} + T\Delta S_{\text{Tor}} + \alpha_1 \Delta E_{\text{Hbond}} + \alpha_2 \Delta E_{\text{HBDsol}} + \alpha_3 \Delta E_{\text{SolEl}} + \alpha_4 \Delta E_{\text{HPhob}} + \alpha_5 Q_{\text{size}} \]

where \( \Delta E_{\text{IntFF}} \) is the change in van der Waals interactions of the ligand and receptor and the internal force-field energy of the ligand, \( T\Delta S_{\text{Tor}} \) is the change in free energy due to conformational entropy and weighted \( (\alpha_1 - \alpha_5) \), \( \Delta E_{\text{Hbond}} \) is the hydrogen bond term, \( \Delta E_{\text{HBDsol}} \) accounts for the disruption of hydrogen bonds with solvent, \( \Delta E_{\text{SolEl}} \) is the solvation electrostatic energy change upon binding, \( \Delta E_{\text{HPhob}} \) is the hydrophobic free energy gain, and \( Q_{\text{size}} \) is the ligand size correction term [26] (http://www.molsoft.com/gui/start-dock.html#interaction-restraints).

The highest scoring predicted docked poses were visualized with ICM Browser, a free downloadable software [27] (V.3.8–5; http://www.molsoft.com/icm_browser.html).

**Binding affinity and free energy prediction**

Prior to binding affinity prediction, the ligand-receptor complexes from ICM were minimized using the USCF chimera default protocol [28]. Preddicta (http://www.scfbio-iitd.res.in/software/drugdesign/preddicta.jsp), an all-atom energy-based computational protocol, was used to approximate DNA-ligand binding affinity [29]. Calculated binding energies (cbe) from preddicta have been shown to have high correlation coefficients of 0.95 (\( R^2 = 0.90 \)) and 0.96 (\( R^2 = 0.93 \)), using linear regression plots against experimental binding free energies (\( \Delta G^\circ \)) and change in thermal melting temperature \( \Delta T_m \) respectively [29]. The energy function used for the calculated DNA-ligand binding energy was represented by the equation below:

\[ \Delta G_{\text{cbe}} = \Delta H_{\text{el}} + \Delta H_{\text{vdw}} - T\Delta S_{\text{rot}}^* + \Delta G_{\text{w}}^* \]

where \( \Delta G_{\text{cbe}} \) is the calculated binding energy, \( \Delta H_{\text{el}} \) is the electrostatic term, \( \Delta H_{\text{vdw}} \) is the van der Waals term, \( T\Delta S_{\text{rot}}^* \) represents the rotational and translational entropy changes on complex formation, and \( \Delta G_{\text{w}}^* \) is a hydration term. The overall \( \Delta G_{\text{cbe}} \) was used to predict \( \Delta T_m \) and \( \Delta G^\circ \) for docked complexes using the equations below:

\[ \Delta G_{\text{pred}}(\text{predicted}) = (\Delta G_{\text{cbe}} - 62.215) / 7.909 \]

\[ \Delta T_m(\text{predicted}) = (\Delta G_{\text{cbe}} - 2.438) / (-1.468) \]

**Molecular dynamics (MD) simulation**

To study the behavior of the docked ligand within the minor groove, the top scoring docked poses in PDB format from congocidine congeners and the tris-benzimidazoles (S3 Data) were exported from ICM version 3.83 to Desmond version 5.3 [30] for MD simulation, prior to performing the MD simulation. The DNA-ligand docked complexes were preprocessed using Prepwizard tool. A solvation model of a Monte-Carlo-equilibrated, transferable intermolecular potential three-point (TIP3P) water bath was used, with box shape orthorhombic boundary conditions, buffer box size calculation method, distances of 10 Å × 10 Å × 10 Å, and a minimized box volume. For DNA-congocidine 2, DNA-congocidine 3, and DNA-tris-benzimidazole docked complexes, 14 Na\(^+\), 15 Na\(^+\), and 15 Na\(^+\) ions, respectively, were used for
neutralization. Finally, after these initial equilibration conditions, MD simulation was performed by applying the OPLS3 force field, and the MD simulations were run for 5 ns at a default temperature of 300 K. During the MD simulation, intermediate structures were saved at a time interval of 10 ps and were superimposed with their native structures to deduce the root mean squared deviation (RMSD) of the ligand. The MD trajectories were visualized, animations were rendered, and 2D ligand interaction diagrams were systematically sampled at intervals of 100 frames to analyze the ligand-receptor complex behavior in the system.

SwissADME prediction

*In silico* drug-related properties like LogP and solubility were carried out by SwissADME [31](http://www.swissadme.ch/), an online server that predicts Absorption Distribution Metabolism Excretion (ADME) parameters.

**Results**

**Docking and redocking results**

The binding score (S) from congocidine /netropsin redocking to the minor groove was found to be approximately (-43.35), with an RMSD to the 473D native derivative of 0.22 Å (Fig 2 and S1 Data). This (S) score may serve as a critical value in determining an approximation of the expected docking score for the tested minor groove binders used in this study.

To establish if the congocidine congeners and the tris-benzimidazole derivative had significant binding ability to the 50 (GTATATAC) 2 duplex, congocidine congeners and tris-benzimidazole were docked to the DNA duplex (Table 1 and S2 Data). The top five stacked conformer poses from the docked complexes were found to have a range of -47.22 to -57.83 for congocidine 2, -39.40 to -47.27 for congocidine 3, and -42.56 to -50.29 for the tris-benzimidazole. For the tested minor groove binders in this study, the score range was comparable to those observed in congocidine -39.37 to -43.35. A redocking replicate of congocidine using the 50 (GCTATATACG) 2 duplex showed the score was within the range of -39.37 to -43.35 (S2 Data). Moreover, based on a benchmarked analysis of the ICM algorithm, a score of -32 or lower is considered significant (http://www.molsoft.com/icmpro/faq-docking.html#faq-score). This score has been used in various studies to discriminate binders from non-binders, with more negative scores representing more likely binding interactions and higher binding affinity of a particular ligand [32,33]. From the stacked conformers in this study, all of the top five docked poses for minor groove binders had the score (S) less than -32, strongly suggesting that both the congocidine congeners and tris-benzimidazole could significantly bind to the TATATA motifs like congocidine.

From the docked poses of congocidine 2, congocidine 3, and tris-benzimidazole, the complete coverage of the TATATA region was observed in both forward and reverse orientation of the ligand to the self-complementary sequence 50 (GTATATAC) 2, a familiar binding pattern characterized by hydrogen bonding of the amide nitrogen NH to acceptor atoms of N3 adenine (A), and O2 to thymine (T) was observed for the sampled top five docked conformer poses of congocidine congeners to the central 50 TATATA (Fig 3A and 3B, S2 Data). A similar binding pattern was also observed for the tris-benzimidazole top five conformers docked to the central TATATA. The inner facing NH groups of the benzimidazole subunits of the tris-benzimidazole participated in hydrogen bonding with acceptor atoms of N3 adenine (A), and O2 to thymine (T) bases of the duplex 50 (GTATATAC)2 DNA, in a manner analogous to that observed in congocidine and its congeners (Fig 3C, S2 Data), showing that these minor groove binders could function as bioisosteres of each other, to some extent.
Additionally, from the top five sampled stacked conformers of congocidine congeners, the possibility of hydrogen bonding between terminal NH groups and the O atoms of the DNA strands was observed. This may have resulted from the increased degrees of freedom of the flexible terminal NH groups that brought the groups within the hydrogen bonding distance (Fig 3A and S2 Data). A similar observation was made involving the flexible 3-amino-1-pyrrolidinyl group at the terminal of the tris-benzimidazole, where a possibility of hydrogen bonding with the O4' atom of the DNA strands and O2' of cytosine 19 was observed (Fig 3C and S2 Data).

For all minor groove binders, the crescent-shaped curvature of ligands was complementary to the floor of the minor groove and spanned the entire 5' TATATA of the minor groove (Fig 3 and S2 Data). A combination of shape complementarity and the associated favorable van der Waals contribution of the minor groove has been described as one of the decisive factors in the drug binding process [34,35].

From the docking score parameters of minor groove binders with DNA, it was evident that the greatest contributing factor from the ICM scoring function came from van der Waals

Additionally, from the top five sampled stacked conformers of congocidine congeners, the possibility of hydrogen bonding between terminal NH groups and the O atoms of the DNA strands was observed. This may have resulted from the increased degrees of freedom of the flexible terminal NH groups that brought the groups within the hydrogen bonding distance (Fig 3A and S2 Data). A similar observation was made involving the flexible 3-amino-1-pyrrolidinyl group at the terminal of the tris-benzimidazole, where a possibility of hydrogen bonding with the O4' atom of the DNA strands and O2' of cytosine 19 was observed (Fig 3C and S2 Data).

For all minor groove binders, the crescent-shaped curvature of ligands was complementary to the floor of the minor groove and spanned the entire 5' TATATA of the minor groove (Fig 3 and S2 Data). A combination of shape complementarity and the associated favorable van der Waals contribution of the minor groove has been described as one of the decisive factors in the drug binding process [34,35].

From the docking score parameters of minor groove binders with DNA, it was evident that the greatest contributing factor from the ICM scoring function came from van der Waals

Table 1. ICM top 5 docking parameters for minor groove binders.

| NAME             | Score  | Hbond  | Hphob | VwInt  | Eint   | Dsolv | SolEl  |
|------------------|--------|--------|-------|--------|--------|-------|--------|
| Congocidine      | -43.35 | -8.10  | -6.10 | -47.68 | 6.01   | 27.50 | 7.10   |
| Congocidine      | -40.71 | -10.16 | -6.23 | -46.91 | 9.19   | 33.30 | 11.14  |
| Congocidine      | -40.61 | -9.32  | -6.33 | -43.51 | 11.18  | 29.09 | 7.70   |
| Congocidine      | -40.02 | -11.34 | -6.10 | -43.55 | 14.28  | 34.48 | 10.02  |
| Congocidine      | -39.37 | -9.30  | -5.51 | -40.38 | 16.07  | 29.48 | 6.82   |
| Congocidine 2    | -57.83 | -13.44 | -7.41 | -56.33 | 13.60  | 35.23 | 12.21  |
| Congocidine 2    | -54.94 | -12.76 | -7.55 | -55.49 | 12.91  | 35.26 | 12.81  |
| Congocidine 2    | -48.21 | -10.12 | -7.47 | -51.98 | 7.90   | 33.70 | 9.24   |
| Congocidine 2    | -47.48 | -11.04 | -7.64 | -55.70 | 12.07  | 37.30 | 15.61  |
| Congocidine 2    | -47.22 | -10.22 | -7.43 | -51.74 | 8.96   | 33.17 | 11.33  |
| Congocidine 3    | -47.27 | -9.16  | -8.42 | -54.42 | 12.85  | 32.34 | 13.21  |
| Congocidine 3    | -46.70 | -8.56  | -8.65 | -55.09 | 11.91  | 33.47 | 11.75  |
| Congocidine 3    | -44.83 | -8.12  | -8.15 | -53.65 | 10.80  | 33.95 | 9.65   |
| Congocidine 3    | -41.47 | -6.82  | -7.97 | -49.21 | 11.03  | 28.53 | 9.01   |
| Congocidine 3    | -39.40 | -7.32  | -7.96 | -50.34 | 8.61   | 31.12 | 12.83  |
| Tris-benzimidazole| -50.29 | -8.45  | -9.02 | -53.62 | 10.42  | 29.34 | 13.28  |
| Tris-benzimidazole| -47.84 | -9.30  | -8.67 | -48.51 | 9.55   | 29.29 | 12.18  |
| Tris-benzimidazole| -44.08 | -5.89  | -9.16 | -54.48 | 11.35  | 31.60 | 11.72  |
| Tris-benzimidazole| -42.58 | -5.20  | -9.09 | -53.13 | 5.51   | 29.21 | 11.99  |
| Tris-benzimidazole| -42.56 | -6.27  | -7.98 | -47.09 | 5.00   | 25.52 | 10.03  |

aScore is the ICM score (-32 and lower are generally considered good scores)
bHbond is hydrogen bond energy (lower values are better)
cHphob is the hydrophobic energy of the surface exposed to water (lower values are better)
dVwInt is the van der Waals interaction energy (lower values are better)
eEint is the internal conformation energy of the ligand (lower values are better)
fDsolv is the desolvation of exposed h-bond donors and acceptors (lower values are better)
gSolEl is the solvation electrostatic energy change upon binding (lower values are better)
Fig 3. Minor groove binders docking to the central d (GTATATAC) 2: (A) congocidine 2, (B) congocidine 3, and (C) tris-benzimidazole (hydrogen bonds are in dotted spheres).

https://doi.org/10.1371/journal.pone.0221175.g003

Table 2. Binding affinity and free energy prediction of minor groove binders.

| Ligand                | ICM-Score | Total Electrostatics $\Delta H_{el}$ (kcal/mol) | Total van der Waals $\Delta H_{vdw}$ (kcal/mol) | Rotational Entropy $\Delta T AS$ $\eta$ (kcal/mol) | Hydration Free Energy $\Delta G_{w}$ (kcal/mol) | Total energy $\Delta G_{cbe}$ (kcal/mol) | Predicted Delta $\Delta T m$(K) | Predicted Binding Affinity $\Delta G_{pred}$ (kcal/mol) |
|-----------------------|-----------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|----------------------------------|----------------------------------|----------------------------------|
| Netropsin(473D)       | -5.6      | -26.6                                         | 25.5                                          | -11.8                                         | -18.6                                         | 14.3                             | -10.2                            |
| Congocidine redock     | -43.35    | -5.0                                          | -27.9                                        | 25.5                                          | -12.0                                         | -19.5                             | 14.9                             | -10.3                            |
| Congocidine 2          | -57.83    | -6.2                                          | -33.5                                        | 26.0                                          | -15.2                                         | -28.7                             | 21.2                             | -11.5                            |
| Congocidine 2          | -54.94    | -6.4                                          | -33.6                                        | 26.0                                          | -15.9                                         | -29.7                             | 21.9                             | -11.6                            |
| Congocidine 2          | -48.21    | -7.8                                          | -30.3                                        | 26.0                                          | -15.2                                         | -27.3                             | 20.3                             | -11.3                            |
| Congocidine 2          | -47.48    | -5.9                                          | -34.5                                        | 26.1                                          | -15.3                                         | -29.6                             | 21.8                             | -11.6                            |
| Congocidine 2          | -47.22    | -5.9                                          | -31.2                                        | 26.0                                          | -15.2                                         | -26.3                             | 19.6                             | -11.2                            |
| Congocidine 3          | -47.27    | -5.5                                          | -35.0                                        | 26.1                                          | -17.9                                         | -32.3                             | 23.7                             | -12.0                            |
| Congocidine 3          | -46.70    | -5.6                                          | -33.7                                        | 26.1                                          | -18.3                                         | -31.4                             | 23.1                             | -11.8                            |
| Congocidine 3          | -44.83    | -5.8                                          | -34.2                                        | 26.1                                          | -17.0                                         | -30.9                             | 22.7                             | -11.8                            |
| Congocidine 3          | -41.47    | -4.6                                          | -30.2                                        | 26.0                                          | -17.2                                         | -25.5                             | 19.4                             | -11.2                            |
| Congocidine 3          | -39.40    | -4.6                                          | -30.1                                        | 26.0                                          | -16.9                                         | -25.5                             | 19.4                             | -11.1                            |
| Tris-benzimidazole     | -50.29    | -3.4                                          | -37.9                                        | 26.1                                          | -19.9                                         | -35.2                             | 25.6                             | -12.3                            |
| Tris-benzimidazole     | -47.84    | -3.5                                          | -29.5                                        | 26.1                                          | -18.0                                         | -24.9                             | 18.6                             | -11.0                            |
| Tris-benzimidazole     | -44.08    | -3.1                                          | -34.3                                        | 26.1                                          | -19.7                                         | -31                               | 22.8                             | -11.8                            |
| Tris-benzimidazole     | -42.58    | -4.2                                          | -33.9                                        | 26.1                                          | -18.9                                         | -30.9                             | 22.7                             | -11.8                            |
| Tris-benzimidazole     | -42.56    | -2.4                                          | -30.7                                        | 26.0                                          | -17.3                                         | -24.4                             | 18.3                             | -10.9                            |

https://doi.org/10.1371/journal.pone.0221175.t002
interaction energy (Table 1). Higher values were observed from the tris-benzimidazole and congocidine congeners, in comparison with congocidine. This may be attributed to the larger binding length from the extra N-methylpyrrole and benzimidazole rings along the minor groove, in comparison with congocidine. Generally, close van der Waal contacts between sandwiching sugar ring-phosphate backbone chains and unsaturated $\pi$ electrons of the N-methylpyrrole ring in minor groove binders have been shown to play a major role in the stability of the DNA-ligand complexes [36], a similar stabilizing interplay of van der Waal interaction would be manifested in the tris-benzimidazole, where interactions involving the O4' oxygens of the ribose rings are in contact with the unsaturated $\pi$ electrons of the benzimidazole subunits [14].

**Binding affinity and free energy prediction results**

The DNA-ligand binding affinity calculations for the docked complexes of congocidine congeners and the tris-benzimidazole were carried out using preddicta algorithm [29]. Theoretically calculated binding affinities of the sampled top five minimized conformers complexes are summarized in Table 2. For the docked complexes of the reversible minor groove binders (S4 Data), the calculated binding affinities were within the linear interpolation range of the known benchmarked experimental values in the preddicta data set [29]. The calculated total binding energies and binding affinities of the complexes had negative values, reflecting that the drug-DNA interaction was feasible for docked complexes of congocidine congeners and tris-benzimidazole. The ranking order for the binding was again dominated by van der Waal factors, with the longer congocidine congeners and tris-benzimidazole having higher values than congocidine. These results further prove that congocidine congeners and tris-benzimidazole have a binding affinity that is better than congocidine (Table 2).

**MD simulation results**

**Congocidine 2.** The assessment of ligand behavior within the minor groove binding pocket of the DNA-congocidine 2 complex showed the heavy atoms 6 and 9 of the terminal guanidinium portion had the highest root mean square fluctuation (RMSF) (Fig 4A), probably because the NH$_2$ amino group of the guanine base in the minor groove exerted steric hindrance to the entry of the ligand amino group into the minor groove. The least amount of fluctuation was observed in heavy atoms 29, 33, 37, buried in the minor groove. From the 2 dimensional ligand extracts (S5 Data), DNA-congocidine 2 interaction patterns were characterized by hydrogen bonding of amide nitrogen NH to acceptor atoms of N3 adenine and O2 to thymine, with both strands of the DNA duplex 5' (GTATATAC)2, while pi-cationic bonds were observed to exist between both guanidinium and ethanimidamide amino groups and terminal adenine and thymine bases. Water molecules were also observed to bridge terminal hydrogen bonds involving adenine, thymine, and cytosine during the MD simulation within a range cutoff of 4 Å (S5 Data).

Overall, congocidine 2 RMSD remained at approximately 0.8 Å, after the transition from reference conformation at time $t = 0$. Deviations around 0.8 Å had a minimal spread around the mode after 0.5 ns and seemed to have stabilized (Fig 5A). Molecular trajectory visualization of simulated animation (S6 Data) showed that the ligand remained bound in the minor groove during the time course of the simulation.

**Congocidine 3.** In the RMSF analysis of congocidine 3, the least amount of RMSF was observed in heavy atoms, deep in the less solvent exposed part of the minor groove (heavy atoms 29, 33, 17, 37) (Fig 4B). The heavy atoms 29 and 33 had less space to move around, and thus, a lower RMSF of approximately 0.2 Å deviation was observed in this region.
Additionally, the terminal butanenitrile and guanidinium portion of congocidine 3, which are solvent exposed, were found to show high root mean square fluctuations (RMSFs), probably due to steric hindrance from C2 amino group of the guanine base towards the guanidinium amino groups and the increased degrees of freedom of movement of rotatable bonds towards...
the solvent-exposed terminal heavy atoms (Fig 4B). A maximal atomic RMSF of 1.5 Å and 1.4 Å were observed for the heavy atoms 6 and 5 respectively of the guanidinium portion, while a 1.3 Å RMSF was observed for heavy atom 3 of the butanenitrile portion.

Most of the ligand fragments remained within the minor groove, as visualized by animation (S7 Data). The sampled 2-dimensional ligand extraction showed that interactions of DNA-congocidine 3 were characterized by hydrogen bonding of amide nitrogen (NH) to acceptor atoms of N3 adenine (A) and O2 to thymine (T). Moreover, the terminal guanidinium end was also observed to be capable of hydrogen bonding with adenine (A4), water molecules formed bridging interactions with adenine and thymine bases at the floor of the minor groove (S5 Data).

Overall ligand RMSD was centered around 1.2 Å, relative to the reference conformation at time t = 0 and seemed to have stabilized after 1.5 nanoseconds (Fig 5B).

**Tris-benzimidazole.** The terminal portions of tris-benzimidazole, which are solvent exposed, showed high RMSFs, probably due to the increased degree of freedom of the solvent-exposed terminals (Fig 4C). A maximal atomic RMSF of approximately 1.1 Å, involving heavy atom 30 was observed at the methoxyphenyl end while the 3 amino-1-pyrrolidinyl end had a maximal RMSF of 0.8 Å. The least amount of fluctuation was observed in heavy atoms deep in the narrow and less solvent exposed part of the minor groove (heavy atoms 26, 33, 38) (Fig 4C). These bonds probably had less space to move around and were buried within the minor groove, thus, a lower RMSF of slightly above 0.2 Å deviation was observed in these regions. The ligand fragment remained within the minor groove, as visualized by the animation (S8 Data). The sampled 2-dimensional ligand extraction patterns (S5 Data) showed that interactions of DNA-tris-benzimidazole had the inner facing nitrogen atom of the benzimidazole subunits of the tris-benzimidazole, participating in hydrogen bonding with acceptor atoms of N3 adenine (A) and O2 to thymine (T) bases of the duplex 5'-GTATATAC-3' DNA. Moreover, the terminal 3 amino-1-pyrrolidinyl end was also observed to be capable of hydrogen bonding.

Fig 5. RMSD of the average ligand structure as a function of time and stability profiles for the MD simulation: (A) congocidine 2, (B) congocidine 3, and (C) tris-benzimidazole.

https://doi.org/10.1371/journal.pone.0221175.g005
with adenine, thymine and forming a pi-cation bond with cytosine. Water molecules were involved in forming bridging interactions with adenine and thymine at the floor of the minor groove (S5 Data). Overall ligand RMSD was centered between 0.5 Å and 0.6 Å, relative to the start frame (Fig 5C).

**LogP evaluation**

Lead potential evaluation for congocidine 2, congocidine 3, and the tris-benzimidazole by SwissADME revealed low LogP values of -1.53 for congocidine 2 and -0.67 for congocidine 3; these congeners were very soluble (Table 3). The property of solubility for these congeners could be advantageous in parenteral usage, as a drug has to be highly soluble in water to deliver a sufficient quantity of active ingredient in a small volume of pharmaceutical dosage [37]. The tris-benzimidazole predicted lead potential, revealed a higher predicted LogP (lipophilicity) value of 3.45 and poor solubility in water, nonetheless, having a large LogP value has been largely been associated with efficient microencapsulation or formation of liposomes [38]. Liposomes are a widely used successful system when targeting macrophages [39] and macrophages are the primary site for ASFV infection [40]. As such, tris-benzimidazole packaged in liposomes may potentially be engineered to show significant accumulation in macrophages and to minimize potential toxic effects [41,42].

**Discussion**

As an antiviral, congocidine has been shown to inhibit the multiplication of viruses, such as Vaccinia virus [43], Shope fibroma virus [43], and Herpes simplex virus [21]. However, unlike the parent drug congocidine, congocidine tri pyrrole derivatives have been shown to display more potency and less cytotoxicity compared to congocidine and distamycin A [21], making them suitable ligands for targeting the ASFV viral genome, moreover, ASFV post-replicative genes are 80% AT-rich and display apparent conserved sequence similarity in its late gene promoters [10].

From docking and subsequent simulation results of congocidine 2, congocidine 3, and tris-benzimidazole, it was evident that these minor groove binders could significantly dock with the AT elements in the minor groove of duplex d (GTATATAC) 2 with coverage spanning the entire 5’ TATATA sequence. Therefore, a model involving the interaction of minor groove binders studied herein and ASFV late viral promoters may be postulated in the potential inhibition of ASFV late gene transcription. We postulate late gene transcription because it occurs in the cytoplasm, after viral genome replication, and thus the viral genome is accessible to solutes [44]. To further highlight with an example, the B646L gene encoding the major capsid protein p72, has an indispensable 5’ TATATA motif in its core promoter region [8–11]. In our docking and simulation experiment, significant binding to a central 5’ TATATA motif was demonstrated using congocidine congeners and tris-benzimidazole, with significant scores in ICM and good binding affinity using preddicta. Thus, it may be foreseen that congocidine

Table 3. ADME properties of select minor groove binders.

| Compound           | Log P | Solubility     |
|--------------------|-------|----------------|
| Congocidine 1      | -1.59 | Very Soluble   |
| Congocidine 2      | -1.53 | Very soluble   |
| Congocidine 3      | -0.67 | Very soluble   |
| Tris-benzimidazole | 3.45  | Poorly Soluble |
| Hoechst 33258      | 2.56  | Moderately soluble |

https://doi.org/10.1371/journal.pone.0221175.t003
Congeneres and tris-benzimidazoles have the potential to bind conserved 5' TATATA promoter motifs including B646L[8], A224L[45], B438L[46], C129R, E165R[47] and I329L[10], or at least conserved AT-rich late promoter 4-mer motifs (S4 Data) in ASFV, and may thereby affect the transcription of multiple ASFV late genes via steric interference, involving melting and unwinding of DNA or interfere with transcription factors that rely on direct or indirect anchorage to AT-rich motifs. One such transcription factor, pB263R, having TATA-binding protein-like features, has been predicted to exist in ASFV [48]. TATA-binding protein (TBP) typically binds to TATA motifs and is a primary anchor of other transcription factors involved in binding to DNA [9].

Consistent with our postulated ASFV TBP/DNA inhibition by congocidine congeners and the tris-benzimidazole in ASFV, studies have shown that Vaccinia virus, a nucleocytoplasmic large DNA virus, has intermediate and late promoter elements that are targeted by TBP [49]. Moreover, intermediate and late gene transcription processes in Vaccinia virus are inhibited by the minor groove binders bisbenzimidazole [7] and distamycin A [49,50]. It turns out that Vaccinia virus has indispensable conserved late TAAAT(G/A) and intermediate TAAAT promoters [7, 8] while ASFV has indispensable conserved late TATA-like promoter motifs ATAT, TATA, ATAA, and TATAA [9,10]. These motifs are consistent with the binding requirements of MGBs and TBPs. In addition, evaluations by gel mobility shift assays have shown that minor groove binders are effective inhibitors of DNA/TBP interactions [51], leading to transcription stagnation [49–52]. The likelihood of ASFV inhibition through transcription stagnation involving AT-rich late promoters is thereby somewhat predictable, using both congeners and tris-benzimidazoles.

Conclusion

In this study, we examined how less toxic congocidine congeners and a tris-benzimidazole bioisostere could be used for targeting of ASFV temporal transcription processes. The results of this in silico study showed, for the first time, how minor groove binders could be used in targeting conserved late gene AT motifs in ASFV that are important for transcription. While our findings are largely in silico and provide a model for understanding, explaining and exploitation of the potential inhibition of ASFV transcription, future experimental verification, both in vivo and in vitro, is necessary.

Supporting information

S1 Data. ICM congocidine redocked.
(ZIP)

S2 Data. ICM files Congo 2, Congo3, Tribz.
(ZIP)

S3 Data. Simulation input PDBs.
(ZIP)

S4 Data. Minimized PDB for predictta.
(ZIP)

S5 Data. 2D ligand extract files.
(ZIP)

S6 Data. Congocidine 2 simulated animation.
(ZIP)
S7 Data. Congocidine 3 simulated animation.
(ZIP)

S8 Data. Tris-benzimidazole simulated animation.
(ZIP)

Author Contributions
Conceptualization: Dickson Kinyanyi, Peris Amwayi, Mark Wamalwa, George Obiero.
Data curation: Dickson Kinyanyi.
Formal analysis: Dickson Kinyanyi, Peris Amwayi, Mark Wamalwa, George Obiero.
Investigation: Dickson Kinyanyi, Mark Wamalwa.
Methodology: Dickson Kinyanyi, George Obiero.
Project administration: Dickson Kinyanyi, Peris Amwayi, Mark Wamalwa.
Supervision: Mark Wamalwa, George Obiero.
Writing – original draft: Dickson Kinyanyi, Peris Amwayi, Mark Wamalwa, George Obiero.
Writing – review & editing: Dickson Kinyanyi, Peris Amwayi.

References
1. Nelson SM, Ferguson LR, Denny WA. Non-covalent ligand/DNA interactions: Minor groove binding agents. Mutat Res. 2007; 623: 24–40. https://doi.org/10.1016/j.mrfmmm.2007.03.012 PMID: 17507044
2. Geierstanger BH, Wemmer DE. Complexes of the minor groove of DNA. Annu Rev Biophys Biomol Struct. 1995; 24: 463–93. https://doi.org/10.1146/annurev.bb.24.060195.002335 PMID: 7663124
3. Karen JM, Barbara P, Kathryn AD, Courtney RD, Coates AM, Buckley JD, et al. A comparison of regular consumption of fresh lean pork, beef and chicken on body composition: A randomized cross-over trial. 2014; 682–696. https://doi.org/10.3390/nu6020682 PMID: 24534884
4. O’Donnell V, Holinka LG, Krug PW, Gladue DP, Carlson J, Sanford B, et al. African Swine Fever Virus Georgia 2007 with a Deletion of Virulence-Associated Gene 9GL (B119L), when Administered at Low Doses, Leads to Virus Attenuation in Swine and Induces an Effective Protection against Homologous Challenge. J Virol. 2015; 89: 8556–66. https://doi.org/10.1128/JVI.00969-15 PMID: 26063424
5. Lown JW, Krowicki K, Balzarini J, Newman RA, Clercq E De. Novel Linked Antiviral and Antitumor Agents Related to Netropsin and Distamycin: Synthesis and Biological Evaluation. J Med Chem. 1989; 32: 2368–2375. https://doi.org/10.1021/jm00130a024 PMID: 2592118
6. Beerman TA, Wojnarowski JM, Sigmund RD, Gawron LS, Rao KE, Lown JW. Netropsin and bis-netropsin analogs as inhibitors of the catalytic activity of mammalian DNA topoisomerase II and topoisomerase cleavable complexes. BBA—Gene Struct Expr. 1991; 1090: 52–60. https://doi.org/10.1016/0167-4781(91)90036-L
7. Yakimovich A, Huttunen M, Zehnder B, Coulter LJ, Gould V, Schneider C, et al. Inhibition of poxvirus gene expression and genome replication by bisbenzimid derivatives. J Virol. 2017, 91: 1–15. https://doi.org/10.1128/JVI.00838-17 PMID: 28659488
8. Garcia-Escudero R, Viruela E. Structure of African swine fever virus late promoters: requirement of a TATA sequence at the initiation region. J Virol. 2000; 74: 8176–82. https://doi.org/10.1128/jvi.74.17.8176-8182.2000 PMID: 10933729
9. Oliveira GP, Andrade AC dos SP, Rodrigues RAL, Arantes TS, Boratto PVM, Silva LKDS, et al. Promoter Motifs in NCLDV's: An Evolutionary Perspective. Viruses. 2017; 9: 16. https://doi.org/10.3390/v9010016 PMID: 28117683
10. Rodriguez JM, Salas ML. African swine fever virus transcription. Virus Res. Elsevier B.V.; 2013; 173: 15–28. https://doi.org/10.1016/j.virusres.2012.09.014 PMID: 23041356
11. Oliveira GP, de Aquino ILM, Luiz APMF, Abraham JS. Putative Promoter Motif Analyses Reinforce the Evolutionary Relationships Among Faustoviruses, Kaumoebavirus, and Asfarvirus. Front Microbiol. 2018; 9: 1041. https://doi.org/10.3389/fmicb.2018.01041 PMID: 29875752
12. Yoon C, Privé GG, Goodsell DS, Dickerson RE. Structure of an alternating-B DNA helix and its relationship to A-tract DNA. Proc Natl Acad Sci U S A. 1988; 85: 6332–6. https://doi.org/10.1073/pnas.85.17.6332 PMID: 341099

13. Coll M, Aymami J, van der Marel GA, van Boom JH, Rich A, Wang AH. Molecular Structure of the Netropsin-d(CGCGATATCGCG) Complex: DNA Conformation in an Alternating AT Segment. Biochemistry. 1989; 28: 310–320. https://doi.org/10.1021/bi00445a042 PMID: 2539859

14. Carrondo MA, Coll M, Aymami J, Wang AH, van der Marel GA, van Boom JH, et al. Binding of a Hoechst dye to d(CGCGATATCGCG) and its influence on the conformation of the DNA fragment. Biochemistry. 1989; 28: 7849–59. https://doi.org/10.1021/bi004445a047 PMID: 2482071

15. Harshman KD, Dervan PB. Molecular recognition of B-DNA by Hoechst 33258. Nucleic Acids Res. 1985; 13: 4825–4835. https://doi.org/10.1093/nar/13.12.4825 PMID: 2410856

16. Gresh N, Pullman B. A theoretical study of the nonintercalative binding of berenil and stilbamidine to double-stranded (dA-dT)n oligomers. Mol Pharmacol. 1984; 25: 452–8. Available: http://www.ncbi.nlm.nih.gov/pubmed/6727867 PMID: 6727867

17. Zakrzewska K, Lavery R, Pullman B. Theoretical studies of the selective binding to DNA of two nonintercalating ligands: netropsin and SN 18071. Nucleic Acids Res. 1983; 11: 8825–39. https://doi.org/10.1093/nar/11.24.8825 PMID: 6324104

18. Shaikh SA, Ahmed SR, Jayaram B. A molecular thermodynamic view of DNA–drug interactions: a case study of 25 minor-groove binders. 2004; 429: 81–99. http://www.ncbi.nlm.nih.gov/pubmed/15288812

19. Kim S, Thiessen PA, Bolton EE, Chen J, Fu G, Gindulyte A, et al. PubChem Substance and Compound databases. Nucleic Acids Res. 2016; 44: D1202–13. https://doi.org/10.1093/nar/gkv951 PMID: 26400175

20. Abagyan R, Totrov M, Kuznetsov D. ICM-A new method for protein modeling and design: Applications to docking and structure prediction from the distorted native conformation. J Comput Chem. 1994; 15: 488–506. https://doi.org/10.1002/jcc.540150503

21. Bialer M, Yagen B, Mechoulam R, Becker Y. Structure-activity relationships of pyrrole amidine antiviral antibiotics. 2. Preparation of mono- and tripyrrole derivatives of congocidine. J Med Chem. 1980; 23: 1144–8. Available: http://www.ncbi.nlm.nih.gov/pubmed/6252323 https://doi.org/10.1021/jm00184a018 PMID: 6252323

22. Aymami J, Nunn CM, Neidle S. DNA minor groove recognition of a non-self-complementary AT-rich sequence by a tris-benzimidazole ligand. Nucleic Acids Res. 1999; 27: 2691–8. https://doi.org/10.1093/nar/27.13.2691 PMID: 10373586

23. Abrescia NG, Malinina L, Fernandez LG, Huynh-Dinh T, Neidle S, Subiran JA. Structure of the oligonucleotide d(CGTATATACG) as a site-specific complex with nickel ions. Nucleic Acids Res. 1999; 27: 1593–9. https://doi.org/10.1093/nar/27.7.1593 PMID: 10075989

24. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The Protein Data Bank. 2000; 28: 235–242.

25. Ruben A, Maxim T. Biased Probability Monte Carlo Conformational Searches and Electrostatic Calculations for Peptides and Proteins. J Mol Biol. 1994; 3: 983–1002. https://doi.org/10.1006/jmbi.1994.1052

26. Schapira M, Totrov M, Abagyan R. Prediction of the binding energy for small molecules, peptides and proteins. J Mol Recognit. 1999; 12: 177–90. https://doi.org/10.1002/(SICI)1099-1352(19990506)12:3<177::AID-JMR451>3.0.CO;2-Z PMID: 10398408

27. Raush E, Totrov M, Marsden BD, Abagyan R. A new method for publishing three-dimensional content. PLoS One. 2009; 4: e7394. https://doi.org/10.1371/journal.pone.0007394 PMID: 19841676

28. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF Chimera—a visualization system for exploratory research and analysis. J Comput Chem. 2004; 25: 1605–12. https://doi.org/10.1002/jcc.20084 PMID: 15264254

29. Shaikh SA, Jayaram B. A swift all-atom energy-based computational protocol to predict DNA-ligand binding affinity and ΔTm. J Med Chem. 2007; 50: 2240–2244. https://doi.org/10.1021/jm060542c PMID: 17419602

30. Bowers KJ, Chow DE, Xu H, Dror RO, Eastwood MP, Gregersen BA, et al. Scalable Algorithms for Molecular Dynamics Simulations on Commodity Clusters. ACM/IEEE SC 2006 Conference (SC’06). IEEE: 2006. pp. 43–43. 10.1109/SC.2006.54

31. Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-like-ness and medicinal chemistry friendliness of small molecules. Sci Rep. Nature Publishing Group; 2017; 7: 42717. https://doi.org/10.1038/srep42717 PMID: 28256516
32. Lam PC-H, Abagyan R, Totrov M. Ligand-biased ensemble receptor docking (LigBEnD): a hybrid ligand/receptor structure-based approach. J Comput Aided Mol Des. Springer International Publishing; 2018; 32: 187–198. https://doi.org/10.1007/s10822-017-0058-x PMID: 28887659

33. Bavan S, Sherman B, Luetje CW, Abaffy T. Discovery of novel ligands for mouse olfactory receptor MOR42-3 using an in silico screening approach and in vitro validation. PLoS One. 2014; 9: e92064. https://doi.org/10.1371/journal.pone.0092064 PMID: 24637889

34. Spitzer GM, Welzenbohn B, Markt P, Kirchmair J, Langer T, Liedl KR. Hydrogen-bonding patterns of minor groove binder—DNA complexes reveal criteria for discovery of new scaffolds. J Chem Inf Model. 2009; 49: 1063–1069. https://doi.org/10.1021/ci800459f PMID: 19275189

35. Fuchs JE, Spitzer GM, Javed A, Biela A, Kreutz C, Welzenbohn B, et al. Minor groove binders and drugs targeting proteins cover complementary regions in chemical space. J Chem Inf Model. 2011; 51: 2223–2232. https://doi.org/10.1021/ci200237c PMID: 21819135

36. Coll M, Aymami J, Van der Marel GA, Van Boom JH, Rich A, Wang AHJ. Molecular structure of the netropsin-d(CGCGATATCGCG) complex: DNA conformation in an alternating AT segment. Biochemistry. 1989; 28: 310–320. https://doi.org/10.1021/bi00427a042 PMID: 25398595

37. Savjani KT, Gajjar AK, Savjani JK. Drug solubility: importance and enhancement techniques. ISRN Pharm. 2012; 2012. https://doi.org/10.5402/2012/195727 PMID: 22830056

38. Nil T, Ishii F. Encapsulation efficiency of water-soluble and insoluble drugs in liposomes prepared by the microencapsulation vesicle method. Int J Pharm. 2005; 298: 198–205. https://doi.org/10.1016/j.ijpharm.2005.04.029 PMID: 15951143

39. Kelly C, Jefferies C, Cryan S-A. Targeted liposomal drug delivery to monocytes and macrophages. J Drug Deliv. 2011; 2011: 727241. https://doi.org/10.1155/2011/727241 PMID: 21512579

40. Galindo I, Cuesta-Geijo MA, Hlavova K, Zemerevichinov DA, Sidorkin VA, et al. The effectivity analysis of accumulation of liposomal, micellar, and water-soluble forms of diminazene in cells and in organs. Drug Deliv. 2008; 13: 351–5. https://doi.org/10.1080/10717540500459084 PMID: 18677310

41. Tang J, Fu H, Kuang Q, Zhang L, Zhang Q, Liu Y, et al. Liposomes co-modified with cholesterol anchored cleavable PEG and octaarginines for tumor targeted drug delivery. J Drug Target. Elsevier Ltd; 2014; 22: 313–26. https://doi.org/10.3109/1061186X.2013.875029 PMID: 24404866

42. Staroverov SA, Pritsensky D V, Yermilov DN, Gabalov KP, Zemerevichinov DA, Sidorkin VA, et al. The effectivity analysis of accumulation of liposomal, micellar, and water-soluble forms of diminazene in cells and in organs. Drug Deliv. 2008; 13: 351–5. https://doi.org/10.1080/10717540500459084 PMID: 18677310

43. Becker Y, Asher Y, Zakay-Rones Z. Congocidine and distamycin A, antipoxvirus antibiotics. Antimicrob Agents Chemother. 1972; 1: 483–8. https://doi.org/10.1128/aac.1.6.483 PMID: 43769089

44. Hernandez B, Guerra M, Salas ML, Andretis G. African Swine Fever Virus Undergoes Outer Envelope Disruption, Capsid Disassembly and Inner Envelope Fusion before Core Release from Multivesicular Endosomes. PLOS Pathog. 2016; 12: 1–32. https://doi.org/10.1371/journal.ppat.1005595 PMID: 27110717

45. Chacon MR, Almazan F, Nogal ML, Vinuela E, Rodriguez JF. The African Swine Fever Virus IAP Homolog Is a Late Structural Polypeptide. Virology. 1995; 214: 670–674. https://doi.org/10.1006/viro.1995.0083 PMID: 8553574

46. Galindo I, Vin E, Carrascosa AL. Characterization of the African swine fever virus protein p49: a new late structural polypeptide. J Gene. 2000; 27: 107–116. https://doi.org/10.1007/s10822-000-0006-3 PMID: 10926815

47. Oliveros M, Garcia-escudero R, Alejo R, Vinuela E, Salas ML, Salas AL. African Swine Fever Virus dUTPase Is a Highly Specific Enzyme Required for Efficient Replication in Swine Macrophages. J Virol. 1999; 73: 8934–8943. PMID: 10515998

48. Kinyanyi D, Obiero G, Obiero GFO, Amwayi P, Mwaniki S, Wamalwa M. In silico structural and functional prediction of African swine fever virus protein-B263R reveals features of a TATA-binding protein. PeerJ. 2018; 6: e4396. https://doi.org/10.7717/peerj.4396 PMID: 29492339

49. Knutson BA, Liu X, Oh J, Broyles SS. Vaccinia Virus Intermediate and Late Promoter Elements Are Targeted by the TATA-Binding Protein. J Virol. 2006; 80: 6784–6793. https://doi.org/10.1128/JVI.02705-05 PMID: 16809284
52. Bellorini M, Moncollin V, D’Incalci M, Mongelli N, Mantovani R. Distamycin A and tallimustine inhibit TBP binding and basal in vitro transcription. Nucleic Acids Res. 1995; 23: 1657–1663. https://doi.org/10.1093/nar/23.10.1657 PMID: 7784168